Amirthalingam Palanisamy
Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Saudi Arabia.
Curr Drug Saf. 2025 May 7. doi: 10.2174/0115748863367086250420011411.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely accepted for managing Type 2 diabetes mellitus. However, numerous drug-related problems (DRPs) have recently been reported about GLP-1 RAs.
The present descriptive study aimed to compile and report the DRPs of various GLP-1 RAs.
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess. The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
Overall, 315952 potential side effects (PSEs) were reported regarding GLP-1 RAs in VigiAccess under injury, poisoning, and procedural complications. Out of 315952 PSE reports, 83210 were DRPs of GLP-1 RAs. Most of them belong to Dulaglutide (23861; 28.68%), followed by tirzepatide (23274; 27.97%), exenatide (18449; 22.17%), semaglutide (11790; 14.97%), and liraglutide (5767; 6.93%). Among the patient-related DRPs, incorrect dose administered (17797; 42.42%), and most of the reports documented for tirzepatide (9993; 23.82%), dulaglutide (4581; 10.92%), and exenatide (2557; 6.10%); however, semaglutide (414; 0.99%), and liraglutide (249; 0.59%), have minor reports documented. Off-label use (13600), most of which were from tirzepatide (4945; 17.59%), followed by semaglutide (4176; 14.85%), liraglutide (1853; 6.59%), exenatide (1530; 5.44%), and dulaglutide (1087; 3.87%).
Qualified healthcare practitioners must educate the patients administering the GLP- 1 RAs to minimize preventable DRPs. Also, careful and frequent monitoring of GLP-1 RAs improves therapeutic outcomes by ruling out DRPs. Healthcare practitioners should comply with approved therapeutic guidelines to enhance the quality of GLP-1 RAs treatment.
胰高血糖素样肽-1受体激动剂（GLP-1 RAs）在2型糖尿病管理中被广泛接受。然而，最近有许多关于GLP-1 RAs的药物相关问题（DRPs）被报道。
本描述性研究旨在汇总并报告各种GLP-1 RAs的DRPs。
从VigiAccess的损伤、中毒及手术并发症类别中提取所有GLP-1 RAs（包括艾塞那肽、利司那肽、利拉鲁肽、度拉鲁肽、司美格鲁肽和替尔泊肽）报告的DRPs。采用欧洲药物治疗护理网络协会（PCNE）的药物相关问题分类（第9.1版）将DRPs分为与患者相关、与医疗实践相关以及与患者或医疗实践相关三类。
总体而言，在VigiAccess的损伤、中毒及手术并发症类别下，共报告了315952例关于GLP-1 RAs的潜在副作用（PSEs）。在315952份PSE报告中，83210份是GLP-1 RAs的DRPs。其中大多数属于度拉鲁肽（23861例；28.68%），其次是替尔泊肽（23274例；27.97%）、艾塞那肽（18449例；22.17%）、司美格鲁肽（11790例；14.97%）和利拉鲁肽（5767例；6.93%）。在与患者相关的DRPs中，给药剂量错误（17797例；42.42%），大多数报告记录的是替尔泊肽（9993例；23.82%）、度拉鲁肽（4581例；10.92%）和艾塞那肽（2557例；6.10%）；然而，司美格鲁肽（414例；0.99%）和利拉鲁肽（249例；0.59%）的相关报告较少。超说明书用药（13600例），其中大多数来自替尔泊肽（4945例；17.59%），其次是司美格鲁肽（4176例；14.85%）、利拉鲁肽（1853例；6.59%）、艾塞那肽（1530例；5.44%）和度拉鲁肽（1087例；3.87%）。
合格的医疗从业者必须对使用GLP-1 RAs的患者进行教育，以尽量减少可预防的DRPs。此外，对GLP-1 RAs进行仔细且频繁的监测，通过排除DRPs可改善治疗效果。医疗从业者应遵守批准的治疗指南，以提高GLP-1 RAs治疗的质量。
